2-acylaminopropoanol-type glucosylceramide synthase inhibitors

US9745294B2 · kind B2 · utility

Assignee

• Genzyme Corporation · US

Inventors

• Craig Siegel · Woburn, US
• Cecilia M. Bastos · Grafton, US
• David J. Harris · Lexington, US
• Angeles Dios · Ashland, US
• Edward R. Lee · Natick, US
• Richard A. Silva · Needham, US
• Lisa M. Cuff · Leominster, US
• Mikaela Levine · Swampscott, US
• Cassandra Celatka · Hull, US
• Frederic Vinick · Mechanicville, US
• Thomas H. Jozefiak · Rochester, US
• Yibin Xiang · Dracut, US
• John Kane · Maynard, US
• Junkai Liao · Andover, US

Key dates

• Filing date: Dec 16, 2014
• Grant date: Aug 29, 2017
• Expiry date: Dec 16, 2034

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D413/14
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

A compound is represented by Structural Formula (I):or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of treating a subject in need thereof comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. The subject has type 2 diabetes; renal hypertrophy or hyperplasia associated with diabetic nephropathy; Tay-Sachs; Gaucher's; or Fabry's disease. Methods of decreasing plasma TNF-α, lowering blood glucose levels, decreasing glycated hemoglobin levels, inhibiting glucosylceramide synthase, and lowering glycosphingolipid concentrations in a subject in need thereof respectively comprise administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof.